Farmas USA

ayer volvimos a cerrar por encima de la MM50

Parece que va bien la cosa ...

NVAX

Y de esta pájara ...  grafico semanal ... si fuera otra recompraba esta semana mismo .. no se no se ... pito pito ... maldito juez cuanto tarda en decidirse, leñe!

AMRN

OJITO con la gripe aviar que en USA no se va, se queda

http://www.nbcnews.com/news/us-news/first-nebraska-cases-bird-flu-confirmed-flock-1-7-million-n358001

NVAX

por enésima vez en los dos últimos años a noticia venta, no hay otra.

OXGN

Movimiento y subida en pre por la designación de nuevo CEO se deduce, que estaban sin, y por sus credenciales.

Schwieterman was Medicine Branch Chief and Immunology and Infectious Disease Branch Chief in Division of Clinical Trials at the FDA.

los de Motley Fool

"Top-line results from these ongoing pivotal studies are expected out by year's end, according to today's press release. The odd part, though, is that the market is clearly doubting the drug's chances of meeting its primary endpoint, given Threshold's sub-$300 million market cap.

My take is that this has more to do with the indication than the drug. Advanced pancreatic cancer has proven to be an extremely difficult disease to treat, with many experimental drugs failing to show any clinical benefit whatsoever.

That said, evofosfamide's midstage results, when used in conjunction with Gemzar, were encouraging. Namely, the combo delivered a 41% reduction in the risk for disease progression or death, compared to the current standard of care.

While there is no guarantee the drug can replicate these results in a larger trial, I think this stock is certainly worth keeping tabs on heading into this data release. "

http://www.fool.com/investing/general/2015/05/12/why-shares-of-threshold-pharmaceuticals-inc-broke.aspx

THLD

Joer con las KIPS....-70%

y eso que solo ha bajado 0,1$ !!
KIPS

esa no la llevabas, no?